Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared a post on X by Viviana Cortiana, Medical Student at the University of Bologna, about a paper they co-authored with colleagues published in Clinical Hematology International:
“Extremely proud of our MedNews Week team and their hard work to make this important piece a reality. Thank you so much to Global Oncology Leader Dr. Amer Zeidan of Yale School of Medicine for your great mentorship and continued support.”
Quoting Viviana Cortiana’s post:
“We are excited to share MedNews week’s recent review, which reflects on the evolution and future directions of myelodysplastic syndromes (MDS) treatment, from hypomethylating agents to precision medicine, targeted therapy, and immunotherapy.
This article was inspired in part by the valuable insights shared by Amer Zeidan during his Keynote at MedNews Week, and we are very grateful to him for the opportunity to learn from his expertise, other as witnessing his passion.
A sincere thank you to the editorial team at IACH, especially Mohamad Mohty and Dr. Tetsuzan Ron, for their guidance and support. We have been very inspired by the IACH’s continued investment in younger and future generations of hemato-oncologists.
Huge congratulations to proud of the young and committed team who were directly involved: Vallabhaneni Sree Harshitha, Jenna Ghazal, Kennedy Itodo, Taha Kassim Dohadwala,and thanks to Yan Leyfman, Chandler Park, for their continued guidance.”
Title: Beyond Hypomethylating Agents: Novel Therapies and Targeted Approaches
Authors: Viviana Cortiana, Harshitha Vallabhaneni, Jenna Ghazal, Kennedy Itodo, Taha Kassim Dohadwala, Chandler Park, Yan Leyfman
You can read the Full Article in Clinical Hematology International.
Read more posts featuring Yan Leyfman on OncoDaily.
